Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.

HOME
>
論文・技術情報
>
Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.

アブストラクト	Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse Event Reporting System (2017-2024), we evaluated formulation- and sex-specific associations. Among 31 774 semaglutide cases, Wegovy demonstrated the strongest signal for ION (reporting odds ratio (ROR)=74.89) compared with Ozempic (ROR=18.81). Sex-stratified analyses showed higher odds in men (ROR=116.37), and multivariable regression confirmed greater risk with Wegovy versus Ozempic (adjusted OR (AOR)=4.74) and in men versus women (AOR=3.33). These findings highlight a potential dose-dependent safety concern that warrants urgent prospective evaluation to guide prescribing and regulatory policy.
ジャーナル名	The British journal of ophthalmology
Pubmed追加日	2026/3/11
投稿者	Lakhani, Moiz; Al-Ani, Abdullah; Popovic, Marko; Benard-Seguin, Etienne; Margolin, Edward
組織名	Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.;Department of Surgery, Section of Ophthalmology, University of Calgary, Calgary,;Alberta, Canada.;Department of Ophthalmology and Visual Sciences, University of Toronto, Toronto,;Ontario, Canada.;Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada;edmargolin@gmail.com.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/41807083/